Press Release
Global Barrette’s Esophagus Market, by Treatment Type (GERD Medicines, Photodynamic Therapy, Radiofrequency Ablation, Endoscopic Mucosal Resection, Esophagectomy), By Treatment Providers (Hospitals, Ambulatory Surgical Center, Clinics), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, & Africa) is expected to grow at a significant CAGR for the period between 2019 and 2027.
As per the report, growing prevalence of gastroesophageal reflux disease (GERD) and poor management of GERD are prime factors driving growth of Barrette’s esophagus treatment market. Barrett’s esophagus is a serious complication chronic of chgastroesophageal reflux disease, and its high prevalence is leaving significant economic impact on global healthcare system. According to US Surveillance Epidemiology and End Results (SEER), 10% of the GERD patients develop Barrett’s esophagus. Low treatment rate for GERD is another major factor leading to the increased prevalence of Barrett’s esophagus. Risk factors for the development of Barrett’s disease also include obesity and tobacco smoking, but GERD is the major risk factor. Costs due to poorly treated GERD with Barrett’s esophagus represent a substantial burden for the healthcare systems. For instance, according to study conducted by Universitat de Barcelona and University of Naples Italy, the estimated cost for the healthcare systems for the population with poorly treated GERD with Barrett’s esophagus was found to be €18 million in Spain, € 12 million in Germany and € 7 million in Germany, in 2015. Furthermore, improving diagnosis rates for Barrett’s esophagus is expected to drive the market for Barrett’s esophagus over the forecast period. A study from Mayo clinic suggests that the concurrent increase number of endoscopies performed annually has improved the ability to diagnose Barrett’s esophagus.
MMC Study identifies some of the key participating players in Barrett’s esophagus market globally are GlaxoSmithKline Plc., Pfizer Inc., AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Johnson and Johnson, Eisai Inc., Takeda Pharmaceuticals etc. among others,
